Literature DB >> 35261006

Long-term predictors of death among Tunisian patients presenting for non ST-elevation acute coronary syndrome.

Walid Jomaa, Ouday Benabdeljelil, Ikram Chamtouri, Wajih Abdallah, Khaldoun Ben Hamda, Faouzi Maatouk.   

Abstract

BACKGROUND: Coronary artery disease is the leading cause of death in emerging countries. Contemporary data about clinical profile and prognosis in Tunisian patients presenting for non ST-elevation acute coronary syndrome (NSTE-ACS) are lacking. AIM: We sought to study the risk profile and 3-year mortality predictors in Tunisian patients presenting for NSTE-ACS in the contemporary setting.
METHODS: In this single center study, data about all consecutive patients presenting to our center for NSTE-ACS from April 2014 to July 2016 were extracted and outcomes exhaustively updated. 3-year mortality predictors were determined by multivariable survival analysis.
RESULTS: A total of 340 patients were included, of which 204 (61.8%) were male. Mean age was 63.6 ± 10.3 years. Prevalence of diabetes mellitus, hypertension and smoking was 57.3%, 62.4%, and 45.3%, respectively. In-hospital, 6, 12 and 36-month mortality rate was 2.3%, 3.2%, 7.1% and 15.2%, respectively. In multivariable survival analysis, independent predictors of death were age >75 (HR=5.45, 95% CI: 2.9-10.03, p<0.001), ST-segment deviation (HR=1.86, 95% CI: 1.04-3.33, p=0.036), anemia (HR=2.56, 95% CI: 1.41-4.67, p=0.002), left ventricular ejection fraction (LVEF) <40% (HR=3.5, 95% CI: 1.84-6.67, p<0.001) and a Global Registry of Acute Coronary Events (GRACE) score ≥140 (HR=2.38, 95% CI: 1.02-5.57, p=0.044).
CONCLUSION: In Tunisian patients presenting for NSTE-ACS, long-term mortality was high. Advanced age, ST-segment deviation, anemia, LVEF <40% and a GRACE score ≥140 were independent long-term predictors of death.

Entities:  

Mesh:

Year:  2021        PMID: 35261006      PMCID: PMC8796684     

Source DB:  PubMed          Journal:  Tunis Med        ISSN: 0041-4131


Introduction

Acute coronary syndromes (ACS) are a leading cause of death and disability worldwide and particularly in emergent countries 1, 2. In Middle-Eastern and North African countries, where income per capita has improved over the last few decades, a concomitant metamorphosis in diet, lifestyle and social habits has occurred resulting in a substantial increase in the prevalence of coronary artery disease (CAD) risk factors 3, 4. Alongside with these modifications in risk profile, antithrombotic therapies and coronary revascularization techniques have undergone dramatic improvements with notably the wide use of double antiplatelet therapy and percutaneous coronary intervention (PCI) with drug eluting stents (DES) 5. In Tunisia, some recently published reports addressed management strategies and early prognosis in patients presenting for ST-elevation myocardial infarction (STEMI) in contemporary practice 6, 7. However, data about risk profile, clinical course and long-term prognosis in patients presenting for non-ST elevation acute coronary syndrome (NSTE-ACS) are nearly absent. Thus, we performed the present study to establish the cardiovascular risk profile, early and long-term prognoses of patients presenting with NSTE-ACS and to determine long term predictive factors of death in this population.

Methods

Study population and design.

In this single center study, we retrospectively extracted data about all consecutive patients aged 18 and older admitted to our cardiology department in a major Tunisian tertiary care facility for NSTE-ACS suspicion, between April 2014 and July 2016. NSTE-ACS was suspected in the presence of any chest pain or discomfort at rest suggestive of myocardial ischemia during at least 10 minutes. Electrocardiogram (ECG) was performed in all patients in less than 10 minutes from first medical contact for NSTE-ACS characterization. Patients presenting with persistent ST-segment elevation on ECG were excluded. We also excluded from the analysis patients for whom transthoracic echocardiography (TTE), and/or when performed, cardiac resonance magnetic imaging eventually confirmed a specific non ischemic, pericardial or myocardial affection. Baseline characteristics and clinical data upon presentation and during hospital stay were extracted from medical files. Routine biology tests including at least two separate cardiac troponin I assays withdrawn six hours apart, were performed in all patients. According to our local protocols, troponin assay was considered positive if one value at least was >0.06 µg/L. Creatinine clearance was calculated using the Modification of Diet in Renal Disease (MDRD) formula 8 and a value <30 mL/min designated severe chronic kidney disease (CKD). Anemia was defined as a blood hemoglobin rate <13 g/dL in men and <12 g/dL in women. The Global Registry of Acute Coronary Events (GRACE) risk score was calculated for risk stratification using the web calculator available on https://www.outcomes-umassmed.org/risk_models_grace_orig.aspx. TTE was performed in all patients and left ventricular ejection fraction (LVEF) was determined in two- and four-chamber views using the Simpson formula. All patients received upon presentation 300 or 600 mg clopidogrel, orally in loading dose, followed by 75 mg daily thereafter, and 250 mg aspirin followed by 125 mg daily thereafter. Anticoagulation with subcutaneous enoxaparin at the dose of 1000 IU/10 kg every 12 hours was administered for at least 6 days, or until invasive coronary angiography (ICA) was performed. Intravenous unfractionated heparin was used instead in patients with a creatinine clearance <30 mL/min. Other pharmacological treatments such as betablockers, angiotensin-converting enzyme inhibitors and statins were administered as guideline directed 9, and in the absence of contra-indications. During hospital course, patients presenting with recurrent symptoms, dynamic ST-segment changes on ECG, those presenting a rise or fall of cardiac troponin and patients with a calculated GRACE risk score ≥140 were referred in 24 to 48 hours to a so called invasive strategy with ICA and ad hoc PCI of the culprit vessel as assessed by the operator. Patients presenting multivessel disease on ICA did not undergo ad hoc PCI and were referred to heart team discussion for choosing the adequate revascularization option (i.e. PCI, surgical revascularization or conservative medical treatment). In the latter subgroup, patients referred to conservative medical treatment after heart team discussion were so due either to the absence of significant coronary stenosis or the presence of severe coronary disease non amenable to revascularization. On the other hand, patients with no ECG changes, negative ischemia biomarkers and no ischemic symptoms recurrence were referred to a so called conservative strategy. Treadmill ECG was therefore performed within 48 to 72 hours from admission and if positive, patient was referred to ICA. In case of inability or contraindication to treadmill ECG, coronary computed tomography (CCT) was performed.

Outcomes.

For the purpose of the present study, in-hospital events reported were bleeding, heart failure, and death. Bleeding was defined as any overt digestive or urinary bleeding or access related bleeding in patients treated invasively. Long term follow-up was completed in all patients and included rehospitalization for ischemic recurrence or heart failure, ischemia driven revascularization at any delay and death at 6, 12 and 36 months. Follow-up data were extracted from medical files and systematically confirmed or completed by phone calls in all patients. Additionally, crude in-hospital and long-term mortality rates were reported according to the GRACE risk score category (≥140 or <140) on-admission. Long-term survival trends were established according to relevant clinical variables collected upon admission. 3-year independent predictors of death in the overall population were determined.

Statistical analysis.

Categorical variables were presented as absolute values and percentages and continuous variables as means ± standard deviation (SD). Baseline characteristics and outcomes were compared between genders. Proportions were compared using Pearson chi-square test or Fisher exact test when appropriate. Means were compared using Student t-test for independent samples. Kaplan-Meier survival curves over the 3-year follow-up period were established and survival function tested for a set of categorical variables using the log-rank test. Variables that led a p<0.25 on log-rank test were included in a Cox regression multivariate survival model. Variables tested comprised age >75, hypertension, diabetes mellitus, anemia, severe CKD, heart failure on-presentation, ST segment deviation, positive troponin assay, LVEF <40% and a GRACE score ≥140. Multivariable adjusted hazard ratio (HR) with accompanying 95% confidence intervals were reported. A value of p<0.05 was set for statistical significance. All analyses were performed using Statistical Package for Social Sciences (SPSS) V. 21 for Windows.

Results

A total of 340 patients were included in the current study. Baseline characteristics of the study population are reported in Table 1 . Mean age was 63.6 ± 10.3 years and 204 (61.8%) patients were male. Prevalence of diabetes mellitus was 57.3% in the overall population and was significantly higher in women compared to men (72.5% vs. 53.9%, p=0.001). Prevalence of hypertension was also higher in women (80.9% vs. 50%, p<0.001) whereas tobacco smoking was significantly higher in men (74.5% vs. 1.5%, p<0.001). Upon presentation, angina pectoris was present in 327 (96.4%) patients and heart failure in 46 (13.5%) patients. Cardiogenic shock was reported in only two (0.6%) patients. ECG was normal in 128 (37.6%) patients and showed an ST-segment depression in 102 (30%) patients. Troponin assay was positive in 194 (57.1%) patients. Mean calculated GRACE score was 102 ± 30 in the overall population and 46 (13.5%) patients had a GRACE score ≥140 with no significant difference between genders.

Table 1. Baselinecharactheristics

Total population N=340

Male N= 204

Female N=136

P

Age

63.69 ± 10.37

62.14 ± 11.18

66.03 ± 9.67

0.084

NSTE-ACS diagnosis

   NSTEMI

194 (57.1%)

122 (59.8%)

72 (52.9%)

0.21

   Unstable angina

146 (42.9%)

82 (40.2%)

64 (47.1%)

0.21

Medical history

   Hypertension

212 (62.4%)

102 (50%)

110 (80.9%)

<0.001

   Diabetes mellitus

195 (57.3%)

110 (53.9%)

98 (72.5%)

0.001

   Smoker

154 (45.3%)

152 (74.5%)

2 (1.5%)

<0.001

   Dyslipidemia

68 (20%)

26 (12.7%)

42 (30.04%)

0.01

   Percutaneous coronary    intervention

78 (22.9%)

50(24.5%)

28 (20.5%)

0.129

   Coronary artery bypass graft

6 (1.7%)

4(1.9%)

2 (1.47%)

0.73

   CKD

22 (6.4%)

10 (4.9%)

12 (8.8%)

0.01

   TIA/Stroke

14 (4.1%)

6 (2.1%)

8 (5.8 %)

0.18

   Atrial fibrillation

10 (2.9%)

4 (1.96%)

6 (4.4%)

0.19

   Peripheral arterial disease

30 (8.9%)

21 (10.29%)

9 (6.6%)

0.02

Clinical presentation

   Angina

327 (96.4%)

199 (97.5%)

128 (94.1%)

0.03

   Heart rate

78.82 ± 18.04

77.92 ±16.76

80.18 ± 19.8

0.7

   Heart failure on-presentation

46 (13.5%)

34 (16.7%)

12 (8.8%)

0.038

   ST segment deviation

102 (30%)

46 (22.54%)

56 (41.17%)

<0.001

   Anemia

80 (23.5%)

25 (12.2%)

55 (40.4%)

<0.001

   Serum glucose (mmol/l)

10.9 ± 2.55

10.6 ± 2,6

11.37 ± 2.76

0.13

   Serum creatinine (µmol/l)

109.68 ± 109

84.35 ± 38.8

147.67 ± 159.6

<0.001

   Positive troponin assay

194 (57.1%)

122 (59.8%)

72 (52.9%)

0.21

   LVEF <40%

44 (12.9%)

39 (19.1%)

5 (3.67%)

0.01

   GRACE score

102 ± 30.27

99.65 ± 30.72

106.67 ± 29.14

0.55

   GRACE score >140

46 (13.5%)

24 (10.7%)

22 (16.17%)

0.24

CKD: chronic kidney disease, GRACE: Global Registry of Acute Coronary Events, LVEF: left ventricular ejection fraction, NSTE-ACS: non ST-elevation acute coronary syndrome, NSTEMI: non ST-elevation myocardial infarction, TIA: transient ischemic attack.

Regarding management, 276 (81.1%) patients underwent an invasive strategy whereas 64 (18.8%) were part of the conservative strategy group (Table 2 ). Compared to female gender, prevalence of male gender was significantly higher in the invasive strategy group (85.2% vs. 75%, p=0.017). One hundred ninety six (57.6%) patients underwent myocardial revascularization either by PCI (45%) or CABG (12.6%) with no significant difference between genders regarding revascularization modality.

Table 2. Management strategy in study population.

Total population N=340

Male N= 204

Female N=136

P

Invasive strategy

276 (81.1%)

174 (85.2%)

102 (75%)

0.017

   PCI

153 (45%)

99 (48.5%)

54 (39.7%)

0.52

   CABG

43 (12.6%)

31 (15.1%)

12 (8.8%)

0.18

   Conservative medical    treatment

80 (23.5%)

44 (21.5%)

36 (26.4%)

0.07

Conservative strategy

64 (18.7%)

30 (14.6%)

34 (24.9%)

0.017

   Treadmill ECG

44 (12.9%)

15 (7.3%)

29 (21.3%)

0.03

   CCT

20 (5.8%)

15 (7.3%)

5 (3.6%)

0.01

CABG : Coronary artery bypass grafting, CCT : Coronary computed tomography, ECG : electrocardiogram, PCI: percutaneous coronary intervention.

In-hospital and long-term outcomes are presented in Table 3 . Overall in-hospital mortality rate was 2.3% with no significant difference between men and women. Rehospitalization for ischemic recurrence or heart failure occurred in 74 (21.7%) patients at a mean delay of 225 ± 214 days from index episode. Ischemia driven revascularization occurred in 41 (12%) patients at a mean delay of 182 ± 180 days. Mortality at 6, 12 and 36 months was 3.2%, 7.1% and 15.2%, respectively (Table 3 ). In comparison to patients with a GRACE score <140, in-hospital, 6-, 12- and 36-month mortality rates were significantly higher in those with a GRACE score ≥140 (Table 4 ). Results of log-rank test for survival according to these variables are depicted in Table 5 . In multivariable survival analysis over 3-year follow-up period, independent predictors of death were an age >75 (HR=5.45, 95% CI: 2.9-10.03, p<0.001), ST-segment deviation (HR=1.86, 95% CI: 1.04-3.33, p=0.036), anemia (HR=2.56, 95% CI: 1.41-4.67, p=0.002), LVEF <40% (HR=3.5, CI: 1.84-6.67, p<0.001) and a GRACE score ≥140 (HR=2.38, 95% CI: 1.02-5.57, p=0.044) (Table 5 ).

Table 3. In-hospital and long-term outcomes.

Total population N=340

Male N= 204

Female N=136

P

In-hospital outcomes

   Heart failure

46 (13.5%)

34 (16.7%)

12 (8.8%)

0.026

   Bleeding

30 (8.8%)

14 (6.8%)

16 (11.7%)

0.11

   Death

8 (2.3%)

6 (2.9%)

2 (1.4%)

0.38

Follow-up

   Rehospitalisation

74 (21.7%)

54 (26.5%)

22 (16.1%)

0.04

   Revascularisation

41 (12%)

22 (10.7%)

19 (13.9%)

0.9

   6-month mortality

11 (3.2%)

7 (3.4%)

4 (2.9%)

0.8

   12-month mortality

24 (7.1%)

11 (5.3%)

13 (9.5%)

0.14

   3-year mortality

52 (15.2%)

26 (12.7%)

26 (19.1%)

0.11

Table 4. In-hospital and long-term mortality according to GRACE Score

GRACE score ≥140

GRACE score <140

p

In-hospital mortality

4 (8.7%)

4 (1.4%)

0.02

6-months mortality

5 (10.9%)

6 (2%)

0.002

12-months mortality

12 (26.1%)

12 (4.1%)

<0.001

36-months mortality

25 (54.3%)

27 (9.2%)

<0.001

Table 5. Independent predictors of death at 3 years in multivariable Cox regression.

Log rank analysis

Cox regression

Log rank

P

HR

95% CI

P

Age >75

95.51

<0.001

5.45

2.9-10.03

<0.001

Hypertension

3.26

0.071

1.63

0.83-3.18

0.15

Diabetes mellitus

1.46

0.225

1.27

0.61-2.65

0.52

Heart failure on-presentation

35.54

<0.001

1.18

0.49-2.85

0.7

ST-segment deviation

5.25

0.022

1.86

1.04-3.33

0.036

Positive troponin assay

13.82

<0.001

0.52

0.23-1.14

0.52

Anemia

28.08

<0.001

2.56

1.41-4.67

0.002

Severe CKD

2.67

0.1

0.71

0.16-3.07

0.71

LVEF <40%

31.25

<0.001

3.5

1.84-6.67

<0.001

GRACE score ≥140

74.11

<0.001

2.38

1.02-5.57

0.044

Abbreviations as for Table 1 .

Discussion

In the present study, we aimed at depicting the clinical and risk profile of patients presenting for NSTE-ACS in the current Tunisian healthcare context. We also presented therapeutic strategies implemented, early and long-term prognoses in this particular setting and independent predictors of death over a 3-year follow-up period. Major findings yielded by the present analysis could be summarized as follows: (a) we reported a strikingly high prevalence of classic atherosclerosis risk factors in Tunisian patients presenting for NSTE-ACS, (b) although short-term mortality rates were fairly low in the study population, 3-year mortality rate was quite high, and (c) as in other settings, ECG signs, anemia on-admission, low LVEF and a high GRACE risk score have been confirmed as long-term predictors of adverse prognosis in our context. As for several developing countries worldwide, the Tunisian population is witnessing an epidemiological transition characterized by a marked decline over the last decades, of infectious diseases as a cause of death in the adult, and the rise of non-communicable diseases such as cardiovascular diseases and neoplasms 4, 10, 11. Such occurring changes are generally imputed to a so-called “lifestyle westernization” characterized by a substantial increase in carbohydrates and fat diet intake, a sedentary lifestyle, and an alarmingly high prevalence of tobacco smoking across age spectrum. Similar findings have already been reported in Middle-Eastern studies 12, 13. Data about coronary artery disease from North African countries are nonetheless lacking and the impact of the implementation of contemporary therapeutic strategies such as aggressive novel anti-thrombotic regimens and revascularization in the acute setting has not so far been adequately assessed. Previous data from our local and national ST-elevation myocardial infarction (STEMI) registries are in accordance with the results from the present study with regard to the high prevalence of classic risk factors of coronary atherosclerosis 6, 14. Nevertheless, prevalence of such risk factors in the NSTE-ACS setting reported herein is higher. Another peculiar finding brought by the present study is the relatively young age of patients presenting for NSTE-ACS, comparable with that reported in some Middle-Eastern reports, but younger than in western studies15, 16, 17 denoting a more aggressive course of the atherosclerotic disease in our North-African population. Prevalence of cardiovascular risk factors was higher in female patients and distribution according to gender was the same as in previous reports from European cohorts 18. Yet, that did not translate into a significant difference in mortality between the two genders. Another interesting finding yielded by the current study is the relatively low early mortality rates in patients presenting for NSTE-ACS. In-hospital and 6-month outcomes remain comparable to those from other studies 19 and lower than early mortality reported in Tunisian patients presenting for STEMI 6. Nevertheless, overall 3-year mortality was remarkably high (15.2%) and could be attributed to the importance of comorbidities in patients with CAD as a whole, but also in many instances, by an insufficient patient adherence to secondary prevention measures and medical therapies in the Tunisian context. An additional follow-up effort needs to be implemented in healthcare facilities to better quantify and remedy this issue. Another determining factor related to the dire long-term prognosis reported could be the absence of coronary revascularization in many cases due to severe and diffuse CAD. In the current study, 3-year follow-up was reported in all patients. This allowed us to obtain accurate survival trends according to several relevant prognostic factors. Advanced age was independently associated to worse long-term outcomes in survival analysis. These findings are in line with those from major reports but also with results in the STEMI setting 7, 20. ST segment deviation on ECG, anemia and impaired LVEF appeared to be very potent predictors of death at 3-years. ST segment depression, especially when affecting several leads was proved to be well correlated to short and long-term survival in patients with NSTE-ACS 9. Anemia and impaired LVEF were proved to be potent predictors of adverse outcomes across all the ACS spectrum 21, 22. Interestingly, a high GRACE risk score (≥140) was also an independent predictor of death in our multivariate 3-year survival model. The GRACE risk score is a well validated tool for in-hospital and 6-month mortality prediction in patients presenting for ACS 23. Despite not being a validation for longer term death prediction, our findings hint at a possible value of the GRACE score in predicting long-term mortality that needs to be confirmed. In the same vein, in a 10-year follow-up analysis of the Third Randomized Intervention Treatment of Angina (RITA-3) trial 24, the modified post-discharge GRACE score was shown to reliably discriminate patients presenting for NSTE-ACS at higher or lower risk of 10-year mortality.

Study limitations.

Limitations of the present study are inherent to its retrospective and observational character. As a consequence, it did not take into account all potential confounders. Important variables other than studied might not be included in the current survival prediction model. For some variables, statistical significance could not be reached due to the relatively small study population. Finally, we did not perform any comparison according to invasive treatment delays so that we determine what might be the optimal strategy in NSTE-ACS management in our context.

Conclusion

According to the present study, patients presenting for NSTE-ACS in our Tunisian context have a high cardiovascular risk profile. Long-term mortality is high and advanced age, ST segment deviation, anemia, impaired LVEF and high GRACE risk score are independent predictors of death in multivariate survival analysis.

Acknowledgment

All authors have no conflict of interest to declare with regard to all manuscript preparation phases. Total population N=340 Male N= 204 Female N=136 P Age 63.69 ± 10.37 62.14 ± 11.18 66.03 ± 9.67 0.084 NSTE-ACS diagnosis NSTEMI 194 (57.1%) 122 (59.8%) 72 (52.9%) 0.21 Unstable angina 146 (42.9%) 82 (40.2%) 64 (47.1%) 0.21 Medical history Hypertension 212 (62.4%) 102 (50%) 110 (80.9%) <0.001 Diabetes mellitus 195 (57.3%) 110 (53.9%) 98 (72.5%) 0.001 Smoker 154 (45.3%) 152 (74.5%) 2 (1.5%) <0.001 Dyslipidemia 68 (20%) 26 (12.7%) 42 (30.04%) 0.01 Percutaneous coronary    intervention 78 (22.9%) 50(24.5%) 28 (20.5%) 0.129 Coronary artery bypass graft 6 (1.7%) 4(1.9%) 2 (1.47%) 0.73 CKD 22 (6.4%) 10 (4.9%) 12 (8.8%) 0.01 TIA/Stroke 14 (4.1%) 6 (2.1%) 8 (5.8 %) 0.18 Atrial fibrillation 10 (2.9%) 4 (1.96%) 6 (4.4%) 0.19 Peripheral arterial disease 30 (8.9%) 21 (10.29%) 9 (6.6%) 0.02 Clinical presentation Angina 327 (96.4%) 199 (97.5%) 128 (94.1%) 0.03 Heart rate 78.82 ± 18.04 77.92 ±16.76 80.18 ± 19.8 0.7 Heart failure on-presentation 46 (13.5%) 34 (16.7%) 12 (8.8%) 0.038 ST segment deviation 102 (30%) 46 (22.54%) 56 (41.17%) <0.001 Anemia 80 (23.5%) 25 (12.2%) 55 (40.4%) <0.001 Serum glucose (mmol/l) 10.9 ± 2.55 10.6 ± 2,6 11.37 ± 2.76 0.13 Serum creatinine (µmol/l) 109.68 ± 109 84.35 ± 38.8 147.67 ± 159.6 <0.001 Positive troponin assay 194 (57.1%) 122 (59.8%) 72 (52.9%) 0.21 LVEF <40% 44 (12.9%) 39 (19.1%) 5 (3.67%) 0.01 GRACE score 102 ± 30.27 99.65 ± 30.72 106.67 ± 29.14 0.55 GRACE score >140 46 (13.5%) 24 (10.7%) 22 (16.17%) 0.24 CKD: chronic kidney disease, GRACE: Global Registry of Acute Coronary Events, LVEF: left ventricular ejection fraction, NSTE-ACS: non ST-elevation acute coronary syndrome, NSTEMI: non ST-elevation myocardial infarction, TIA: transient ischemic attack. Total population N=340 Male N= 204 Female N=136 P Invasive strategy 276 (81.1%) 174 (85.2%) 102 (75%) 0.017 PCI 153 (45%) 99 (48.5%) 54 (39.7%) 0.52 CABG 43 (12.6%) 31 (15.1%) 12 (8.8%) 0.18 Conservative medical    treatment 80 (23.5%) 44 (21.5%) 36 (26.4%) 0.07 Conservative strategy 64 (18.7%) 30 (14.6%) 34 (24.9%) 0.017 Treadmill ECG 44 (12.9%) 15 (7.3%) 29 (21.3%) 0.03 CCT 20 (5.8%) 15 (7.3%) 5 (3.6%) 0.01 CABG : Coronary artery bypass grafting, CCT : Coronary computed tomography, ECG : electrocardiogram, PCI: percutaneous coronary intervention. Total population N=340 Male N= 204 Female N=136 P In-hospital outcomes Heart failure 46 (13.5%) 34 (16.7%) 12 (8.8%) 0.026 Bleeding 30 (8.8%) 14 (6.8%) 16 (11.7%) 0.11 Death 8 (2.3%) 6 (2.9%) 2 (1.4%) 0.38 Follow-up Rehospitalisation 74 (21.7%) 54 (26.5%) 22 (16.1%) 0.04 Revascularisation 41 (12%) 22 (10.7%) 19 (13.9%) 0.9 6-month mortality 11 (3.2%) 7 (3.4%) 4 (2.9%) 0.8 12-month mortality 24 (7.1%) 11 (5.3%) 13 (9.5%) 0.14 3-year mortality 52 (15.2%) 26 (12.7%) 26 (19.1%) 0.11 GRACE score ≥140 GRACE score <140 p In-hospital mortality 4 (8.7%) 4 (1.4%) 0.02 6-months mortality 5 (10.9%) 6 (2%) 0.002 12-months mortality 12 (26.1%) 12 (4.1%) <0.001 36-months mortality 25 (54.3%) 27 (9.2%) <0.001 Log rank analysis Cox regression Log rank P HR 95% CI P Age >75 95.51 <0.001 5.45 2.9-10.03 <0.001 Hypertension 3.26 0.071 1.63 0.83-3.18 0.15 Diabetes mellitus 1.46 0.225 1.27 0.61-2.65 0.52 Heart failure on-presentation 35.54 <0.001 1.18 0.49-2.85 0.7 ST-segment deviation 5.25 0.022 1.86 1.04-3.33 0.036 Positive troponin assay 13.82 <0.001 0.52 0.23-1.14 0.52 Anemia 28.08 <0.001 2.56 1.41-4.67 0.002 Severe CKD 2.67 0.1 0.71 0.16-3.07 0.71 LVEF <40% 31.25 <0.001 3.5 1.84-6.67 <0.001 GRACE score ≥140 74.11 <0.001 2.38 1.02-5.57 0.044 Abbreviations as for Table 1 .
  23 in total

1.  ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC).

Authors:  Christian W Hamm; Jean-Pierre Bassand; Stefan Agewall; Jeroen Bax; Eric Boersma; Hector Bueno; Pio Caso; Dariusz Dudek; Stephan Gielen; Kurt Huber; Magnus Ohman; Mark C Petrie; Frank Sonntag; Miguel Sousa Uva; Robert F Storey; William Wijns; Doron Zahger
Journal:  Eur Heart J       Date:  2011-08-26       Impact factor: 29.983

2.  2018 ESC/EACTS Guidelines on myocardial revascularization.

Authors:  Franz-Josef Neumann; Miguel Sousa-Uva; Anders Ahlsson; Fernando Alfonso; Adrian P Banning; Umberto Benedetto; Robert A Byrne; Jean-Philippe Collet; Volkmar Falk; Stuart J Head; Peter Jüni; Adnan Kastrati; Akos Koller; Steen D Kristensen; Josef Niebauer; Dimitrios J Richter; Petar M Seferovic; Dirk Sibbing; Giulio G Stefanini; Stephan Windecker; Rashmi Yadav; Michael O Zembala
Journal:  Eur Heart J       Date:  2019-01-07       Impact factor: 29.983

3.  Global perspective on acute coronary syndrome: a burden on the young and poor.

Authors:  Rajesh Vedanthan; Benjamin Seligman; Valentin Fuster
Journal:  Circ Res       Date:  2014-06-06       Impact factor: 17.367

4.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

5.  10-Year Mortality Outcome of a Routine Invasive Strategy Versus a Selective Invasive Strategy in Non-ST-Segment Elevation Acute Coronary Syndrome: The British Heart Foundation RITA-3 Randomized Trial.

Authors:  Robert A Henderson; Christopher Jarvis; Tim Clayton; Stuart J Pocock; Keith A A Fox
Journal:  J Am Coll Cardiol       Date:  2015-08-04       Impact factor: 24.094

6.  [Management of patients treated for acute ST-elevation myocardial infarction in Tunisia: Preliminary results of FAST-MI Tunisia Registry from Tunisian Society of Cardiology and Cardiovascular Surgery].

Authors:  F Addad; J Gouider; E Boughzela; S Kamoun; R Boujenah; H Haouala; H Gamra; F Maatouk; A Ben Khalfallah; S Kachboura; H Baccar; N Ben Halima; A Guesmi; K Sayahi; W Sdiri; A Neji; A Bouakez; K Battikh; R Chettaoui; S Mourali
Journal:  Ann Cardiol Angeiol (Paris)       Date:  2015-11-05

7.  Clinical presentation and outcomes of acute coronary syndromes in the gulf registry of acute coronary events (Gulf RACE).

Authors:  Mohammad Zubaid; Wafa A Rashed; Najib Al-Khaja; Wael Almahmeed; Jawad Al-Lawati; Kadhim Sulaiman; Ahmed Al-Motarreb; Haitham Amin; Jassim Al-Suwaidi; Khalid Al-Habib
Journal:  Saudi Med J       Date:  2008-02       Impact factor: 1.484

8.  Prevalence and prognostic significance of anemia in patients presenting for ST-elevation myocardial infarction in a Tunisian center.

Authors:  Walid Jomaa; Imen Ben Ali; Sonia Hamdi; Mohamed A Azaiez; Aymen El Hraïech; Khaldoun Ben Hamda; Faouzi Maatouk
Journal:  J Saudi Heart Assoc       Date:  2016-10-20

9.  Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015.

Authors:  Gregory A Roth; Catherine Johnson; Amanuel Abajobir; Foad Abd-Allah; Semaw Ferede Abera; Gebre Abyu; Muktar Ahmed; Baran Aksut; Tahiya Alam; Khurshid Alam; François Alla; Nelson Alvis-Guzman; Stephen Amrock; Hossein Ansari; Johan Ärnlöv; Hamid Asayesh; Tesfay Mehari Atey; Leticia Avila-Burgos; Ashish Awasthi; Amitava Banerjee; Aleksandra Barac; Till Bärnighausen; Lars Barregard; Neeraj Bedi; Ezra Belay Ketema; Derrick Bennett; Gebremedhin Berhe; Zulfiqar Bhutta; Shimelash Bitew; Jonathan Carapetis; Juan Jesus Carrero; Deborah Carvalho Malta; Carlos Andres Castañeda-Orjuela; Jacqueline Castillo-Rivas; Ferrán Catalá-López; Jee-Young Choi; Hanne Christensen; Massimo Cirillo; Leslie Cooper; Michael Criqui; David Cundiff; Albertino Damasceno; Lalit Dandona; Rakhi Dandona; Kairat Davletov; Samath Dharmaratne; Prabhakaran Dorairaj; Manisha Dubey; Rebecca Ehrenkranz; Maysaa El Sayed Zaki; Emerito Jose A Faraon; Alireza Esteghamati; Talha Farid; Maryam Farvid; Valery Feigin; Eric L Ding; Gerry Fowkes; Tsegaye Gebrehiwot; Richard Gillum; Audra Gold; Philimon Gona; Rajeev Gupta; Tesfa Dejenie Habtewold; Nima Hafezi-Nejad; Tesfaye Hailu; Gessessew Bugssa Hailu; Graeme Hankey; Hamid Yimam Hassen; Kalkidan Hassen Abate; Rasmus Havmoeller; Simon I Hay; Masako Horino; Peter J Hotez; Kathryn Jacobsen; Spencer James; Mehdi Javanbakht; Panniyammakal Jeemon; Denny John; Jost Jonas; Yogeshwar Kalkonde; Chante Karimkhani; Amir Kasaeian; Yousef Khader; Abdur Khan; Young-Ho Khang; Sahil Khera; Abdullah T Khoja; Jagdish Khubchandani; Daniel Kim; Dhaval Kolte; Soewarta Kosen; Kristopher J Krohn; G Anil Kumar; Gene F Kwan; Dharmesh Kumar Lal; Anders Larsson; Shai Linn; Alan Lopez; Paulo A Lotufo; Hassan Magdy Abd El Razek; Reza Malekzadeh; Mohsen Mazidi; Toni Meier; Kidanu Gebremariam Meles; George Mensah; Atte Meretoja; Haftay Mezgebe; Ted Miller; Erkin Mirrakhimov; Shafiu Mohammed; Andrew E Moran; Kamarul Imran Musa; Jagat Narula; Bruce Neal; Frida Ngalesoni; Grant Nguyen; Carla Makhlouf Obermeyer; Mayowa Owolabi; George Patton; João Pedro; Dima Qato; Mostafa Qorbani; Kazem Rahimi; Rajesh Kumar Rai; Salman Rawaf; Antônio Ribeiro; Saeid Safiri; Joshua A Salomon; Itamar Santos; Milena Santric Milicevic; Benn Sartorius; Aletta Schutte; Sadaf Sepanlou; Masood Ali Shaikh; Min-Jeong Shin; Mehdi Shishehbor; Hirbo Shore; Diego Augusto Santos Silva; Eugene Sobngwi; Saverio Stranges; Soumya Swaminathan; Rafael Tabarés-Seisdedos; Niguse Tadele Atnafu; Fisaha Tesfay; J S Thakur; Amanda Thrift; Roman Topor-Madry; Thomas Truelsen; Stefanos Tyrovolas; Kingsley Nnanna Ukwaja; Olalekan Uthman; Tommi Vasankari; Vasiliy Vlassov; Stein Emil Vollset; Tolassa Wakayo; David Watkins; Robert Weintraub; Andrea Werdecker; Ronny Westerman; Charles Shey Wiysonge; Charles Wolfe; Abdulhalik Workicho; Gelin Xu; Yuichiro Yano; Paul Yip; Naohiro Yonemoto; Mustafa Younis; Chuanhua Yu; Theo Vos; Mohsen Naghavi; Christopher Murray
Journal:  J Am Coll Cardiol       Date:  2017-05-17       Impact factor: 24.094

10.  Baseline characteristics, management practices, and long-term outcomes of Middle Eastern patients in the Second Gulf Registry of Acute Coronary Events (Gulf RACE-2).

Authors:  Khalid F Alhabib; Kadhim Sulaiman; Ahmed Al-Motarreb; Wael Almahmeed; Nidal Asaad; Haitham Amin; Ahmad Hersi; Shukri Al-Saif; Khalid AlNemer; Jawad Al-Lawati; Norah Q Al-Sagheer; Nizar AlBustani; Jassim Al Suwaidi
Journal:  Ann Saudi Med       Date:  2012 Jan-Feb       Impact factor: 1.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.